JMP Securities Reiterates Market Outperform on Cellectis, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities has reiterated its Market Outperform rating on Cellectis (NASDAQ:CLLS) and maintained a price target of $6.
May 31, 2024 | 3:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities has reiterated its Market Outperform rating on Cellectis and maintained a price target of $6. This positive analyst rating could boost investor confidence in the short term.
The reiteration of a Market Outperform rating and a maintained price target of $6 by JMP Securities is a positive signal for investors. This could lead to increased buying interest and a potential short-term price increase for Cellectis.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100